A Phase 2 interventional study of DUR-928 in Primary Sclerosing Cholangitis, sponsored by Durect. Terminated at 4 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-10-17.
Sponsored by Durect (part of Bausch Health Companies Inc.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies in Cholangitis, Sclerosing with a site in United States — 19 open to participants now, 22 under way, 2 of them phase 3. Cholangitis, Sclerosing · United States.
Among the 75 studies in Cholangitis, Sclerosing with a site in United States, this one is the 51st largest by enrollment of the 57 interventional ones that give a count, is one of 5 that started in 2018, is one of 26 in phase 2, and was the 42nd registered.
150 studies on the registry are indexed under Cholangitis, Sclerosing; 40 are open to participants now.
Browse Cholangitis, Sclerosing studies →19 of the 75 studies in Cholangitis, Sclerosing with a site in United States are open now. Recruiting first, the newest first:
Ipsen · Sites in United States, Argentina, Australia and 22 more countries
Ages 18–75
Takeda · Sites in United States
Ages 18–68 · Healthy volunteers
LISCure Biosciences · Sites in United States
Ages 18–75
Mayo Clinic · Sites in United States
Ages 18–75
Elizabeth C. Verna · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 30 Cholangitis, Sclerosing studies recruiting now, 12 (40%) set no upper age limit and 13 (43%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 31 · Phase 3 6
First in 1997; this study’s year is marked. 5 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5 is below the median of 33 across 95 interventional studies indexed under Cholangitis, Sclerosing.
Median enrollment 27 across the 57 interventional studies, 129 across the 18 observational. Of the 48 that completed or were terminated, 25 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 75 have an industry lead sponsor. The 10 most frequent:
This study is registered under Durect, one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Durect is the lead sponsor of 15 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.
Bausch Health Companies Inc. has 1 study filed under Cholangitis, Sclerosing — fewer than ten, so there is no comparison to draw.
4 of the studies in Cholangitis, Sclerosing with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06197308University of MinnesotaEvaluation of an Oral Microbiota-based Therapeutic as a Treatment Option for PSC | 2027-03-31 |
| NCT05295680Aparna GoelOral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis. | 2027-05 |
| NCT05835505Brigham and Women's HospitalDetoxification of the Liver In PSC (Dolphin) | 2027-05-01 |
| NCT05912387Stanford UniversityStatin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study | 2027-05-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 75 studies in Cholangitis, Sclerosing with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a research trial testing DUR-928 (an experimental medication). The purpose of the trial is to assess whether treatment with DUR-928 has any effect on the treatment of Primary Sclerosing Cholangitis (PSC). This trial will also assess safety (side effects).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
10 mg oral suspension
Drug: DUR-928
50 mg oral suspension
Drug: DUR-928
oral suspension daily for 28 days
Percent Change of Alkaline Phosphatase (ALP) From Baseline
Time frame: Day 28 (end of treatment) and Day 56 (end of study/early termination)
Percent Change of Liver Enzymes and Serum Bile Acids (sBA)
Liver enzymes include alanine transaminase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), bilirubin. Percent change from baseline through the end of study treatment (Day 28) and throughout the follow-up period (Day 56).
Time frame: Day 28 and Day 56
Percent of Subjects With Reduction of Serum Alkaline Phosphatase (ALP) From Baseline
Time frame: Day 28 (end of treatment) and Day 56 (end of follow-up)
Percent Change of Selected Biomarkers From Baseline Through the End of Study Treatment and Throughout the Follow-up Period.
Time frame: Day 28 and Day 56
Study was terminated early due to lack of enrollment.
| Milestone | DUR-928 10 mg | DUR-928 50 mg |
|---|---|---|
| Started | 3 | 2 |
| Completed | 3 | 2 |
| Not completed | 0 | 0 |
| percent change | DUR-928 10 mg | DUR-928 50 mg |
|---|---|---|
| Percent change of ALP from baseline to Day 28 | 23.7 ± 10.7 | 16.8 ± 2.97 |
| Percent change of ALP from baseline to Day 56 | 10.7 ± 17.04 | 11.05 ± 8.68 |
Liver enzymes include alanine transaminase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), bilirubin. Percent change from baseline through the end of study treatment (Day 28) and throughout the follow-up period (Day 56).
| percent change | DUR-928 10 mg | DUR-928 50 mg |
|---|---|---|
| percent ALT change from baseline to Day 28 | 32.87 ± 48.87 | 3.0 ± 29.56 |
| percent AST change from baseline to Day 28 | 24.10 ± 35.03 | -20.25 ± 3.23 |
| percent GGT change from baseline to Day 28 | 7.3 ± 4.16 | 8.15 ± 1.49 |
| percent direct bilirubin change from baseline to Day 28 | 14.2 ± 24.61 | 34.6 ± NA |
| percent total bilirubin change from baseline to Day 28 | 12.03 ± 23.09 | 23.85 ± 33.73 |
| percent serum bile acids change from baseline to Day 28 | -13.93 ± 15.00 | -44.10 ± 46.95 |
| percent ALT change from baseline to Day 56 | -9.77 ± 15.30 | -12.7 ± 5.66 |
| percent AST change from baseline to Day 56 | -16.23 ± 9.17 | -9.70 ± 19.09 |
| percent GGT change from baseline to Day 56 | -7.10 ± 11.87 | -3.2 ± 2.26 |
| percent direct bilirubin change from baseline to Day 56 | -12.90 ± NA | 19.20 ± NA |
| percent total bilirubin change from baseline to Day 56 | -24.60 ± 20.46 | 19.14 ± 15.61 |
| percent serum bile acids change from baseline to Day 56 | 35.23 ± 79.79 | -35.75 ± 72.90 |
| Participants | DUR-928 10 mg | DUR-928 50 mg |
|---|---|---|
| subjects with ≥ 40% reduction of serum ALP from baseline at day 28/end of treatment | 0 | 0 |
| subjects with ≥ 40% reduction of serum ALP from baseline at day 56/end of follow-up | 0 | 0 |
No measurements were reported for this outcome.
Collected over 56 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DUR-928 10 mg | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| DUR-928 50 mg | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| Event | DUR-928 10 mg | DUR-928 50 mg |
|---|---|---|
| ELEVATED ALKALINE PHOSPHATASEInvestigations | 0/3 | 1/2 |
| ELEVATED ALTInvestigations | 0/3 | 1/2 |
| ELEVATED ASTInvestigations | 0/3 | 1/2 |
| ELEVATED GGTInvestigations | 0/3 | 1/2 |
| ELEVATED SERUM BILE ACIDSInvestigations | 0/3 | 1/2 |
| LEFT EAR ERYTHEMA PRESENTSkin and subcutaneous tissue disorders | 0/3 | 1/2 |
| DRUG INDUCED LIVER INJURYHepatobiliary disorders | 1/3 | 0/2 |
| WORSENING SINUS BRADYCARDIACardiac disorders | 1/3 | 0/2 |
| EXCESSIVE GAS (FLATUS)Gastrointestinal disorders | 1/3 | 0/2 |
| Age, Categorical(Participants) | DUR-928 10 mg | DUR-928 50 mg | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 3 | 1 | 4 |
| >=65 years | 0 | 1 | 1 |
| Sex: Female, Male(Participants) | DUR-928 10 mg | DUR-928 50 mg | Total |
|---|---|---|---|
| Female | 1 | 1 | 2 |
| Male | 2 | 1 | 3 |
| Ethnicity (NIH/OMB)(Participants) | DUR-928 10 mg | DUR-928 50 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 3 | 2 | 5 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | DUR-928 10 mg | DUR-928 50 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 3 | 1 | 4 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Region of Enrollment(Participants) | DUR-928 10 mg | DUR-928 50 mg | Total |
|---|---|---|---|
| United States | 3 | 2 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2018 to primary completion in Jan 2019, 12 months.
Results were first posted in Oct 2022, 3 years 8 months after primary completion. A results delay was requested in Aug 2020.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Larsucosterol